



Pfizer Reports Third Quarter 2013 Results

Tuesday, October 29, 2013 - 03:00am

Third-Quarter 2013 Reported Revenues(1) of \$12.6 Billion Third-Quarter 2013 Adjusted Diluted EPS(2) of \$0.58 and Reported Diluted EPS(1) of \$0.39 Repurchased \$3.8 Billion and \$13.1 Billion of Common Stock in Third-Quarter and to Date in 2013, Respectively Narrowed Ranges for Certain 2013 Financial Guidance Components

.bwtablebottommargin,.bwtablemarginb{border: none;margin-bottom:10.0px; color: #000 !important;} .bwpadl0{padding-left:0.0px; color: #000 !important;}

.bwcellpaddingleft1,.bwpadl1{padding-left:5.0px;}.bwcellpaddingleft2,.bwpadl2{padding-left:10.0px;}.bwcellpaddingleft3,.bwpadl3{padding-left:15.0px;}.bwcellpaddingleft4,.bwpadl4{padding-left:20.0px;}.bwcellpaddingleft5,.bwpadl5{padding-left:25.0px;}.bwcellpaddingleft6,.bwpadl6{padding-left:30.0px;}.bwcellpaddingleft7,.bwpadl7{padding-left:35.0px;}.bwcellpaddingleft8,.bwpadl8{padding-left:40.0px;}.bwcellpaddingleft9,.bwpadl9{padding-left:45.0px;}.bwcellpaddingleft10,.bwpadl10{padding-left:50.0px;}.bwcellpaddingleft11,.bwpadl11{padding-left:55.0px;}.bwcellpaddingleft12,.bwpadl12{padding-left:60.0px;}.bwcellpaddingleft13,.bwpadl13{padding-left:65.0px;}.bwcellpaddingleft14,.bwpadl14{padding-left:70.0px;}.bwcellpaddingleft15,.bwpadl15{padding-left:75.0px;}.bwcellpaddingleft16,.bwpadl16{padding-left:80.0px;}.bwcellpaddingleft17,.bwpadl17{padding-left:85.0px;}.bwcellpaddingleft18,.bwpadl18{padding-left:90.0px;}.bwcellpaddingleft19,.bwpadl19{padding-left:95.0px;}.bwcellpaddingleft20,.bwpadl20{padding-left:100.0px;}.bwcellpaddingright0,.bwpadr0{padding-

right:0.0px;}.bwcellpaddingright1,.bwpadr1{padding-right:5.0px;}.bwcellpaddingright2,.bwpadr2{padding-right:10.0px;}.bwcellpaddingright3,.bwpadr3{padding-right:15.0px;}.bwcellpaddingright4,.bwpadr4{padding-right:20.0px;}.bwcellpaddingright5,.bwpadr5{padding-right:25.0px;}.bwcellpaddingright6,.bwpadr6{padding-right:30.0px;}.bwcellpaddingright7,.bwpadr7{padding-right:35.0px;}.bwcellpaddingright8,.bwpadr8{padding-right:40.0px;}.bwcellpaddingright9,.bwpadr9{padding-right:45.0px;}.bwcellpaddingright10,.bwpadr10{padding-right:50.0px;}.bwcellpaddingtop1,.bwpadt1{padding-top:10.0px;}.bwcellpaddingtop2,.bwpadt2{padding-top:20.0px;}.bwcellpaddingtop3,.bwpadt3{padding-top:30.0px;}.bwcellpaddingtop4,.bwpadt4{padding-top:40.0px;}.bwcellpaddingtop5,.bwpadt5{padding-top:50.0px;}.bwcellpaddingtop6,.bwpadt6{padding-top:60.0px;}.bwcellpaddingtop7,.bwpadt7{padding-top:70.0px;}.bwcellpaddingtop8,.bwpadt8{padding-top:80.0px;}.bwcellpaddingtop9,.bwpadt9{padding-top:90.0px;}.bwcellpaddingtop10,.bwpadt10{padding-top:100.0px;}.bwcellpaddingtop11,.bwpadt11{padding-top:110.0px;}.bwcellpaddingtop12,.bwpadt12{padding-top:120.0px;}.bwcellpaddingtop13,.bwpadt13{padding-top:130.0px;}.bwcellpaddingtop14,.bwpadt14{padding-top:140.0px;}.bwcellpaddingtop15,.bwpadt15{padding-top:150.0px;}.bwcellpaddingtop16,.bwpadt16{padding-top:160.0px;}.bwcellpaddingtop17,.bwpadt17{padding-top:170.0px;}.bwcellpaddingtop18,.bwpadt18{padding-top:180.0px;}.bwcellpaddingtop19,.bwpadt19{padding-top:190.0px;}.bwcellpaddingtop20,.bwpadt20{padding-top:200.0px;}.bwcellpaddingbottom1,.bwpadb1{padding-bottom:2.0px;}.bwcellpaddingbottom2,.bwpadb2{padding-bottom:3.0px;}.bwcellpaddingbottom3,.bwpadb3{padding-bottom:4.0px;}.bwverticalt{vertical-align:top;}.bwverticalalignmiddle,.bwverticalalignm{vertical-align:middle;}.bwverticalalignbottom,.bwverticalalignb{vertical-align:bottom;}.bwalignl{text-align:left;}.bwalignc{text-align:center;clear:both;}.bwalignr{text-align:right;}.bwsinglebottomborder,.bwsinglebottom{border-bottom:solid black 1.0pt !important;border-right:medium none;border-top:medium none;border-left:medium

Reported Diluted EPS(1) 0.39 0.43 (9%) 2.77 1.09 *

* Calculation not meaningful.

BUSINESS UNIT(4) REVENUES

(\$ in millions)

Favorable/(Unfavorable)

Third-Quarter	Year-to-Date 2013	2012	% Change	2013	2012	% Change
Total	Oper.	Total	Oper.	Specialty Care	Primary Care	Emerging Markets
\$ 10,483	(6%)	(4%)	3,259	3,610	(10%)	(8%)
2,431	2,389	2%	5%	7,466	7,308	2%
2,383	(4%)	(1%)	7,033	7,865	(11%)	(8%)
2,276	5%	5%	407	329	24%	26%
* 229	169	36%	36%	Total	\$ 12,643	\$ 12,953
(7%)	(5%)				(2%)	--
					\$ 38,026	\$ 40,766

* Calculation not meaningful.

SELECTED ADJUSTED COSTS AND EXPENSES(2)

(\$ in millions)

(Favorable)/Unfavorable

Third-Quarter	Year-to-Date 2013	2012	% Change	2013	2012	% Change
Total	Oper.	Total	Oper.	Cost of Sales(2)	Percent of Revenues(2)	SI&A Expenses(2)
\$ 6,601	\$ 6,806	(3%)	1%	17.3%	17.1%	N/A
1,625	1,841	(12%)	(12%)	4,764	5,074	(6%)
(5%)	(3%)	\$ 21,444	\$ 22,633	(5%)	(3%)	Effective Tax Rate(2)
						27.6%
						28.0%

2013 FINANCIAL GUIDANCE(6)

The ranges for certain components of the financial guidance have been narrowed as set forth below.

Adjusted Revenues(2) \$50.8 to \$51.8 billion
(previously \$50.8 to \$52.8 billion)

Adjusted Cost of Sales(2) as a Percentage of Adjusted Revenues(2) 18.0% to 18.5%
(previously 18.0% to 19.0%)

Adjusted SI&A Expenses(2) \$14.2 to \$14.7 billion
(previously \$14.2 to \$15.2 billion)

Adjusted R&D Expenses(2) \$6.3 to \$6.6 billion
(previously \$6.1 to \$6.6 billion)

Adjusted Other (Income)/Deductions(2) Approximately \$400 million
(previously approximately \$800 million)

Effective Tax Rate on Adjusted Income(2) Approximately 28.0% Reported Diluted
EPS(1) \$3.05 to \$3.15
(previously \$3.07 to \$3.22)

Adjusted Diluted EPS(2) \$2.15 to \$2.20
(previously \$2.10 to \$2.20)

EXECUTIVE COMMENTARY

Ian Read, Chairman and Chief Executive Officer, stated, "Overall, I am very pleased with our continued and steady progress, on many fronts, to drive greater value for our shareholders. We continue to generate solid financial results on an operational basis, despite the impact of product losses of exclusivity and the ongoing expiration of the Spiriva collaboration in certain countries as well as the challenging operating environment. Within our innovative businesses, during third-quarter 2013, revenues from our Oncology business increased 26% operationally due to the continued strong performance of new products, primarily Inlyta and Xalkori in several major markets. In addition, other key patent-protected products performed well operationally, notably Lyrica, which grew 11%, and Celebrex, which grew 13%. With regard to recently launched products, Eliquis prescription trends continue to improve, and we recently began our direct-to-consumer campaign in the U.S.; in addition, Xeljanz continues to perform in line with our expectations."

“Over the next several months, we expect to report key clinical data read-outs that will more clearly characterize the strength of our late-stage pipeline. These data read-outs will be across a broad range of both additional indications for currently marketed products and novel compounds, including Prevnar 13 in adults, Xeljanz (psoriasis), dacomitinib, palbociclib, and the staphylococcus aureus vaccine, among others. In addition, we have just initiated a phase 3 program for bococizumab (RN316), our PCSK9 inhibitor for LDL cholesterol reduction, and are initiating a phase 3 program with our collaboration partner Merck for ertugliflozin, our SGLT2 inhibitor for the treatment of type 2 diabetes. We also plan to begin a phase 3 program for our biosimilar of Herceptin for metastatic breast cancer in the next few months. In addition, we are planning to continue development of tanezumab for the treatment of osteoarthritis, chronic low back pain and cancer pain, and have just entered into a collaboration agreement with Eli Lilly & Company to jointly develop and globally commercialize tanezumab,” Mr. Read concluded.

Frank D’Amelio, Chief Financial Officer, stated, “For the first nine months of 2013, our financial performance has been in line with our expectations. Given these results and our continued confidence in the business, we are narrowing the ranges for certain components of our 2013 financial guidance. Also, with our continued strong operating cash flow and proceeds generated from the separations of our Nutrition and Animal Health businesses, we continue to expect to repurchase in the mid-teens of billions of dollars of our common stock this year, with \$13.1 billion repurchased through October 28. Additionally, we will pay approximately \$6.5 billion in dividends.”

QUARTERLY FINANCIAL HIGHLIGHTS (Third-Quarter 2013 vs. Third-Quarter 2012)

Reported revenues⁽¹⁾ decreased \$310 million, or 2%, which reflects an operational decline of \$38 million, or less than 1%, and the unfavorable impact of foreign exchange of \$272 million, or 2%. The operational decrease was primarily the result of the continued erosion for branded Lipitor in the U.S., developed Europe and certain other markets. Additionally, revenues were negatively impacted by other product losses of exclusivity, the ongoing expiration of the Spiriva collaboration in certain countries, decreased government purchases of Prevnar and Enbrel in certain emerging markets, and various other events. Revenues were positively impacted by the overall growth of Lyrica, Enbrel, Inlyta and Xalkori, as well as Celebrex and Xeljanz in the U.S. In addition, reported revenues⁽¹⁾ included \$67 million from the transitional manufacturing and supply agreements with Zoetis⁽³⁾. Business unit revenues were impacted by the following: Specialty Care: Revenues declined 1% operationally, primarily due to the shift in the reporting of Geodon and Revatio revenues in the U.S. and Xalabrand revenues in developed Europe and Australia to the Established Products unit beginning January 1,

2013, which was largely offset by the growth of Enbrel, as well as Prevnar and Xeljanz in the U.S. Primary Care: Revenues decreased 8% operationally, primarily due to the shift in the reporting of Lipitor revenues in developed Europe and Australia to the Established Products unit beginning January 1, 2013, as well as certain other product losses of exclusivity in various markets, including Viagra in most major markets in Europe in June 2013 and Lyrica in Canada in February 2013, and the termination of the co-promotion agreement for Aricept in Japan in December 2012. Additionally, in the U.S. and certain European countries, the co-promotion collaboration for Spiriva is in its final year, which, per the terms of the collaboration agreement, has resulted in a decline in Pfizer's share of Spiriva revenues; and in Australia, Canada and certain other European countries, the Spiriva collaboration has terminated. These declines were partially offset by the strong performance of Celebrex, Chantix, EpiPen, Premarin and Pristiq in the U.S. as well as Lyrica. Emerging Markets: Revenues grew 5% operationally, primarily due to volume growth in China, most notably Lipitor, which was partially offset by the impact of the transfer of certain product rights to the Pfizer-Hisun joint venture in first-quarter 2013. Revenues were also negatively impacted by decreased government purchases of Prevnar and Enbrel, as well as government cost-containment measures, in certain other emerging markets. Full-year 2013 operational revenue growth in emerging markets is expected to be a mid-single-digit percentage. Established Products: Revenues decreased 1% operationally. This performance was driven by the benefit of revenues from products in certain markets that were shifted to the Established Products unit from other business units beginning January 1, 2013, including Lipitor in developed Europe and Australia, as well as the contribution from the collaboration with Mylan Inc. to market generic drugs in Japan. Revenues were unfavorably impacted by the continued erosion of branded Lipitor in the U.S. and Japan. Consumer Healthcare: Revenues increased 1% operationally, primarily due to strong international growth for Centrum as a result of several recent product launches and increased promotional activities in key markets, as well as growth of Emergen-C in the U.S. due to expanded distribution and promotional activities. This growth was partially offset by declines in sales of respiratory and other products in certain international markets due to unfavorable seasonal conditions compared with the year-ago quarter. Oncology: Revenues increased 26% operationally, driven by the continued solid uptake of new products, most notably Inlyta and Xalkori in several major markets. Inlyta's market share continues to increase as patient feedback has been positive both in terms of efficacy and tolerability, and as pricing and reimbursement are being granted in developed Europe. Xalkori prescriptions and new patient starts also continue to increase, driven by initiatives established to improve molecular testing and identify the appropriate patients for this medicine. Adjusted cost of sales, adjusted SI&A expenses and adjusted R&D expenses⁽²⁾ in the aggregate decreased \$341 million, or 5%,

primarily reflecting the benefits of cost-reduction and productivity initiatives, the non-recurrence of the \$250 million payment included in adjusted R&D expenses(2) in the year-ago quarter to obtain the exclusive global over-the-counter rights to Nexium, and the favorable impact of foreign exchange, partially offset by adjusted SI&A expenses(2) to support several new product launches. The increase in Adjusted cost of sales(2) on an operational basis compared with the same period last year reflects a shift in product mix. The effective tax rate on adjusted income(2) declined 0.4 percentage point to 27.6% from 28.0%. This decline was primarily due to the jurisdictional mix of earnings and the extension of the U.S. research and development tax credit that was signed into law in January 2013, partially offset by the non-recurrence of favorable audit settlements with foreign jurisdictions for multiple years in the year-ago quarter. The diluted weighted-average shares outstanding declined by approximately 852 million shares, due to the company's ongoing share repurchase program and the first full-quarter impact of the Zoetis(3) exchange offer, which was completed on June 24, 2013. In addition to the aforementioned factors, third-quarter 2013 reported earnings were favorably impacted by lower charges related to legal matters, lower acquisition-related costs and lower purchase accounting adjustments. Reported earnings were unfavorably impacted by an increased effective tax rate, increased asset impairments and other related charges as well as the non-recurrence of the income from discontinued operations attributable to the company's Animal Health and Nutrition businesses in the year-ago quarter. The effective tax rate on reported income(1) increased in third-quarter 2013 in comparison with the year-ago quarter primarily due to the non-recurrence of favorable settlements in the year-ago quarter with the U.S. Internal Revenue Service, as well as foreign jurisdictions, related to audits for multiple tax years.

RECENT NOTABLE DEVELOPMENTS

Product Developments

Pprevnar Pfizer announced the completion of pneumonia case accrual in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) 65 years of age and older, which was designed to evaluate whether Pprevnar 13 is effective in preventing community-acquired pneumonia caused by the 13 pneumococcal serotypes included in the vaccine. The top-line results are expected to be reported in early 2014. The European Commission (EC) approved Pprevnar 13 for an expanded indication to include adults aged 18 to 49 years for active immunization for the prevention of invasive disease caused by vaccine-type *Streptococcus pneumoniae*. The EC is the first regulatory authority to approve Pprevnar 13 to offer protection against invasive disease at all stages of life.

Xeljanz The phase 3 Xeljanz psoriasis program continues to progress. The top-line results

were announced from the first two (OPT Compare and OPT Retreatment) of five phase 3 clinical trials in adults with moderate-to-severe chronic plaque psoriasis. In OPT Compare, Xeljanz met the primary endpoint of non-inferiority to high-dose Enbrel at the 10 mg twice-daily (BID) dose, but did not at the 5 mg BID dose. In OPT Retreatment, Xeljanz met the primary efficacy endpoints at the 5 and 10 mg BID doses by demonstrating that a greater proportion of patients continuing Xeljanz treatment maintained their response during the treatment-withdrawal phase compared to patients who switched to placebo. Additionally, among patients who lost an adequate response, many were able to recapture their response upon retreatment with Xeljanz. No new safety signals were observed in these two studies. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) confirmed its prior negative opinion for Xeljanz for the treatment of adult patients with moderate-to-severe active RA. The company is currently evaluating the feedback from the CHMP, will determine next steps to resubmit a Marketing Authorization Application to the EMA and anticipates that this will result in a several-year delay. Eliquis -- The U.S. Food and Drug Administration (FDA) accepted for review a supplemental new drug application for Eliquis for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in adult patients who have undergone hip or knee replacement surgery. The PDUFA date for a decision by the FDA is March 15, 2014. Duavee -- The FDA has approved Duavee (0.45 mg/20 mg tablets), a novel therapy for women with a uterus, for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis. Duavee is expected to be available in the U.S. in first-quarter 2014.

Pipeline Developments

Palbociclib -- A phase 3 trial (Study 1023, PALOMA-3) in advanced recurrent breast cancer recently began enrolling patients. This is a randomized global study that will evaluate palbociclib in combination with fulvestrant versus placebo plus fulvestrant in prolonging investigator-assessed, progression-free survival in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer whose disease has progressed after prior endocrine therapy. Bococizumab (RN316) -- The phase 3 program was initiated for the PCSK9 monoclonal antibody to lower LDL cholesterol. This is a global program in more than 22,000 patients, which includes multiple lipid-lowering studies as well as two cardiovascular outcomes studies. This program includes the broadest range of high-risk patients including a focus on patients in greatest need of LDL-lowering. Ertugliflozin -- Pfizer in collaboration with Merck is initiating a phase 3 program for the SGLT2 inhibitor for the treatment of type 2 diabetes. Tanezumab -- Pfizer is planning to continue development of tanezumab for the

treatment of osteoarthritis, chronic low back pain and cancer pain, and has just entered into a collaboration agreement with Eli Lilly & Company to jointly develop and globally commercialize tanezumab, which provides that Pfizer and Lilly will equally share product development expenses as well as potential revenues and certain product-related costs. The tanezumab program currently is subject to a partial clinical hold by the FDA pending submission of nonclinical data to the FDA. Pfizer anticipates submitting that data in the first half of 2014. Under the agreement with Lilly, Pfizer is eligible to receive certain payments from Lilly upon the achievement of specified clinical, regulatory and commercial milestones, including an upfront payment that is contingent upon the parties continuing in the collaboration after receipt of the FDA's response to the submission of the nonclinical data. Both Pfizer and Lilly have the right to terminate the agreement under certain conditions.

Other Developments

Pfizer announced plans to internally separate its commercial operations into three businesses, which will be called the Global Innovative Pharmaceutical business, the Global Vaccines, Oncology and Consumer Healthcare business, and the Global Established Pharmaceutical business. Each of the three businesses will include developed markets and emerging markets. In most countries, the changes will be implemented in fiscal 2014. Beginning with first-quarter 2014 financial results, the company will provide greater financial transparency for each of these three businesses, which will include a 2014 baseline management view of profit and loss for each business.

For additional details, see the attached financial schedules, product revenue tables and disclosure notice.

(1) "Reported Revenues" is defined as revenues in accordance with U.S. generally accepted accounting principles (GAAP). "Reported Net Income" is defined as net income attributable to Pfizer Inc. in accordance with U.S. GAAP. "Reported Diluted EPS" is defined as reported diluted EPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP. (2)

"Adjusted Income" and its components and "Adjusted Diluted Earnings Per Share (EPS)" are defined as reported U.S. GAAP net income(1) and its components and reported diluted EPS(1) excluding purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items. Adjusted Revenues, Adjusted Cost of Sales, Adjusted Selling, Informational and Administrative (SI&A) expenses, Adjusted Research and Development (R&D) expenses and Adjusted Other (Income)/Deductions are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. As described under Adjusted Income in the

Management's Discussion and Analysis of Financial Condition and Results of Operations section of Pfizer's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2013, management uses adjusted income, among other factors, to set performance goals and to measure the performance of the overall company. We believe that investors' understanding of our performance is enhanced by disclosing this measure. See the accompanying reconciliations of certain GAAP reported to non-GAAP adjusted information for the third quarter and first nine months of 2013 and 2012, as well as reconciliations of full-year 2013 guidance for adjusted income and adjusted diluted EPS to full-year 2013 guidance for reported net income(1) and reported diluted EPS(1). The adjusted income and its components and adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.

(3) On June 24, 2013, Pfizer completed the full disposition of Zoetis, Inc. (Zoetis) and, as a result, Pfizer reports the financial results of its Animal Health business as a discontinued operation in the condensed consolidated statements of income for year-to date 2013, and third-quarter and year-to-date 2012. (4) For a description of the revenues in each business unit, see Note 13 to Pfizer's condensed consolidated financial statements included in Pfizer's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2013. (5)

Other represents revenues generated from Pfizer CentreSource, Pfizer's contract manufacturing and bulk pharmaceutical chemical sales organization, and includes, in 2013, revenues related to our transitional manufacturing and supply agreements with Zoetis(3).

(6) The 2013 financial guidance reflects the following: The financial results of the Animal Health business from January 1, 2013 to June 24, 2013, as well as the gain on disposal of Zoetis(3), are presented as a discontinued operation. As a result, they have been excluded from all components of the financial guidance except Reported Net Income(1) and Reported Diluted EPS(1). Reported Net Income(1) and Reported Diluted EPS(1) guidance includes the gain on disposal of Zoetis(3), as well as the financial results of the Animal Health business as follows: January 1, 2013 to February 6, 2013: 100% of Zoetis(3) financial results are included February 7, 2013 to June 24, 2013: 80.2% of Zoetis(3) financial results are included; 19.8% of Zoetis(3) financial results are excluded, as this interest in Zoetis(3) was no longer owned by Pfizer June 24, 2013 through December 31, 2013: no actual or projected financial results of Zoetis(3) are included

In addition, revenues and cost of sales from the transitional manufacturing and supply agreements with Zoetis(3) have been excluded from the applicable Adjusted components of the financial guidance.

The weighted-average shares outstanding used in the computation of Adjusted(2) and Reported(1) Diluted EPS guidance reflects the reduction in shares of Pfizer's outstanding common stock as a result of the Zoetis(3) exchange offer. Since this reduction occurred on June 24, 2013, Adjusted(2) and Reported(1) Diluted EPS guidance reflects only a partial-year benefit. Reported Diluted EPS(1) guidance includes the income from a litigation settlement with Teva Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Ltd. for patent-infringement damages resulting from their "at-risk" launches of generic Protonix in the U.S. Does not assume the completion of any business development transactions not completed as of September 29, 2013, including any one-time upfront payments associated with such transactions. Excludes the potential effects of the resolution of litigation-related matters not substantially resolved as of September 29, 2013. Exchange rates assumed are a blend of the actual exchange rates in effect through September 29, 2013 and the mid-October 2013 exchange rates for the remainder of the year. Reconciliation of the 2013 Adjusted Income(2) and Adjusted Diluted EPS(2) guidance to the 2013 Reported Net Income Attributable to Pfizer Inc. and Reported Diluted EPS Attributable to Pfizer Inc. common shareholders guidance:

(\$ in billions, except per share amounts) Income/(Expense) Net Income Diluted EPS

Adjusted income/diluted EPS(2) guidance	\$14.8 - \$15.2	\$2.15 - \$2.20	Purchase accounting impacts of transactions completed as of September 29, 2013 (3.3) (0.49)
Acquisition-related costs (0.4 - 0.5) (0.06 - 0.07)			Non-acquisition-related restructuring costs (0.6 - 0.8) (0.09 - 0.13)
Certain other items incurred through September 29, 2013	0.3 0.04		Discontinued operations
Reported net income attributable to Pfizer Inc./diluted EPS(1) guidance	\$21.2 - \$21.9	\$3.05 - \$3.15	

Pfizer Inc. AND SUBSIDIARY COMPANIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME(1)
(UNAUDITED) (millions, except per common share data)

	Third-Quarter %	Incr. /
Nine Months %	Incr. /	2013 2012 (Decr.)
Revenues	\$ 12,643	\$ 12,953
(2) \$ 38,026	\$ 40,766	(7)
Costs and expenses:		
Cost of sales(2)	2,287	2,309 (1) 6,792
(4) Selling, informational and administrative expenses(2)	3,395	3,491 (3) 10,203
(6) Research and development expenses(2)	1,627	1,887 (14) 4,867 5,461 (11)
Amortization of intangible assets(3)	1,117	1,211 (8) 3,476 3,889 (11)
Restructuring charges and certain acquisition-related costs	233	312 (25) 547 1,085 (50)
Other (income)/deductions--net(4)	411	937 (56) (514) 3,264
* Income from continuing operations before provision for taxes on income	3,573	2,806 27 12,655 9,165 38
Provision/(benefit) for taxes on income(5)	985	(183) * 3,876 1,622
* Income from continuing operations	2,588	2,989 (13) 8,779 7,543 16
Discontinued operations--net of tax	11	225 (95) 10,719 734
* Net income before allocation to noncontrolling interests	2,599	3,214 (19) 19,498 8,277
* Less: Net income attributable to noncontrolling interests	9	6 50 63 22
* Net income attributable to Pfizer Inc.		

\$ 2,590	\$ 3,208	(19)	\$ 19,435	\$ 8,255	* Earnings per common share--basic: Income from continuing operations attributable to Pfizer Inc. common shareholders	\$ 0.39	\$ 0.40
(3)	\$ 1.26	\$ 1.00	26	Discontinued operations--net of tax	-	0.03	* 1.54 0.10 *
				Net income attributable to Pfizer Inc. common shareholders	\$ 0.39	\$ 0.43	(9) \$ 2.80 \$
				1.10 * Earnings per common share--diluted: Income from continuing operations attributable to Pfizer Inc. common shareholders	\$ 0.39	\$ 0.40	(3) \$ 1.25 \$ 1.00 25
				Discontinued operations--net of tax	-	0.03	* 1.52 0.10 * Net income attributable to Pfizer Inc. common shareholders
				\$ 0.39	\$ 0.43	(9) \$ 2.77	\$ 1.09 * Weighted-average shares used to calculate earnings per common share: Basic
6,938	7,483	Diluted	6,656	7,508	7,016	7,550	

* Calculation not meaningful.

See next page for notes (1) through (5). td> EPS amounts may not add due to rounding. PFIZER INC. AND SUBSIDIARY COMPANIES NOTES TO CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) (1) The financial statements present the three and nine months ended September 29, 2013 and September 30, 2012. Subsidiaries operating outside the United States are included for the three and nine months ended August 25, 2013 and August 26, 2012. On June 24, 2013, we completed the full disposition of our Animal Health business (Zoetis) and recognized a gain of approximately \$10.5 billion (pre-tax) related to this disposal in Discontinued operations--net of tax for the nine months ended September 29, 2013. The operating results of this business are reported as Discontinued operations--net of tax for the nine months ended September 29, 2013 and three and nine months ended September 30, 2012.

On November 30, 2012, we completed the sale of our Nutrition business. The operating results of this business are reported as Discontinued operations--net of tax for the three and nine months ended September 30, 2012. The financial results for the three and nine months ended September 29, 2013 are not necessarily indicative of the results which could ultimately be achieved for the full year. (2) Exclusive of amortization of intangible assets, except as discussed in footnote (3) below. (3) Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function is included in Cost of sales, Selling, informational and administrative expenses or Research and development expenses, as appropriate. (4) Other (income)/deductions--net include the following: Third-Quarter Nine

Months (millions of dollars)

2013

2012

2013

2012

Interest income(a) \$ (94) \$ (109) \$ (291) \$ (275) Interest expense(a) 340 381
1,067 1,149 Net interest expense 246 272 776 874 Royalty-related income (122)
(149) (305) (343) Patent litigation settlement (income)/expense(b) 9 - (1,342) - Other
legal matters, net(c) 1 727 (94) 2,014 Gain associated with the transfer of certain
product rights to an equity-method investment(d) - - (459) - Net gain on asset disposals
(46) (21) (100) (45) Certain asset impairments and related charges(e) 443 14 968 524
Costs associated with the Zoetis IPO(f) - 32 18 93 Other, net (120) 62 24 147
Other (income)/deductions--net \$ 411 \$ 937 \$ (514) \$ 3,264 (a) Interest income
decreased in the third quarter of 2013 as portfolio maturities were invested at lower
rates; however, during the first nine months of 2013, interest income increased due to
higher cash and investment balances. Interest expense decreased in the third quarter
and first nine months of 2013 due to lower outstanding debt, refinancings and lower
rates, and the benefit of the conversion of some fixed-rate liabilities to floating-rate
liabilities. (b) Reflects income from a litigation settlement with Teva Pharmaceutical
Industries Ltd. and Sun Pharmaceutical Industries Ltd. for patent-infringement damages
resulting from their "at-risk" launches of generic Protonix in the United States. (c) In the
first nine months of 2013, primarily includes an \$80 million insurance recovery related to
a certain litigation matter. In the third quarter of 2012, primarily includes a \$491 million
charge related to the resolution of an investigation by the U.S. Department of Justice into
Wyeth's historical promotional practices in connection with Rapamune. In the first nine
months of 2012, primarily includes the aforementioned \$491 million charge related to
Rapamune, a \$450 million settlement of a lawsuit by Brigham Young University related to
Celebrex, and charges for hormone-replacement therapy litigation. (d) In the first nine
months of 2013, represents the gain associated with the transfer of certain product rights
to Pfizer's 49%-owned equity-method investment in China. (e) In the third quarter of
2013, primarily includes a loss on an option to acquire the remaining interest in a 40%-
owned generics company in Brazil (approximately \$220 million), as well as an impairment
charge related to an in-process research and development (IPR&D) compound. In the first

nine months of 2013, also includes impairment charges related to developed technology (for use in the development of bone and cartilage) acquired in connection with our acquisition of Wyeth and two additional IPR&D compounds. In the first nine months of 2012, primarily includes impairment charges related to certain intangible assets acquired in connection with our acquisitions of Wyeth and King Pharmaceuticals Inc. (King), including IPR&D intangible assets. (f) Costs incurred in connection with the initial public offering (IPO) of an approximate 19.8% ownership interest in Zoetis. Includes expenditures for banking, legal, accounting and similar services. (5) The Provision/(benefit) for taxes on income for the third quarter and first nine months of 2012 was favorably impacted by a \$1.1 billion settlement (representing tax and interest) with the U.S. Internal Revenue Service (IRS) related to audits for multiple tax years, as well as the resolution of foreign audits pertaining to multiple tax years. PFIZER INC. AND SUBSIDIARY COMPANIES RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of dollars, except per common share data)

	Quarter Ended September 29, 2013	Purchase Acquisition- Certain GAAP Accounting Related Discontinued Significant Non-GAAP Reported(1)	Adjustments Costs(2)	Operations Items(3)	Adjusted(4)	Revenues
	\$ 12,643	\$ -	\$ -	\$ -	\$ (67)	\$ 12,576
Cost of sales(5)	2,287	(4)	(18)	(87)	2,178	Selling, informational and administrative expenses(5)
	3,395	(1)	-	(43)	3,351	Research and development expenses(5)
	1,627	(1)	-	(1)	1,625	Amortization of intangible assets(6)
	1,117	(1,075)	-	-	42	Restructuring charges and certain acquisition-related costs
	233	(43)	-	(190)	-	Other (income)/deductions--net
	411	121	-	(490)	42	Income from continuing operations before provision for taxes on income
	3,573	960	61	744	5,338	Provision/(benefit) for taxes on income
	985	309	7	172	1,473	Income from continuing operations
	2,588	651	54	-	572	

	3,865	Discontinued operations--net of tax	11	-	(11)	-	Net income attributable to noncontrolling interests
	9	-	(3)	-	6	Net income attributable to Pfizer Inc.	2,590
	651	54	(8)	572	3,859	Earnings per common share attributable to Pfizer Inc.--diluted	0.39
	0.10	0.01	-	0.09	0.58	Nine Months Ended September 29, 2013	Purchase Acquisition- Certain GAAP Accounting Related Discontinued Significant Non-GAAP Reported(1)
	Adjustments Costs(2)	Operations Items(3)	Adjusted(4)	Revenues	\$ 38,026	\$ -	\$ -
	\$ (67)	\$ 37,959	Cost of sales(5)	6,792	16	(101)	(106)
	6,601	Selling, informational and administrative expenses(5)	10,203	5	(8)	(121)	10,079
	Research and development expenses(5)	4,867	1	-	(104)	4,764	Amortization of intangible assets(6)
	3,476	(3,352)	-	-	124	Restructuring charges and certain acquisition-related costs	547
	(155)	(392)	-	Other (income)/deductions--net	(514)	43	-
	836	365	Income from continuing operations before				

provision for taxes on income 12,655 3,287 264 - (180) 16,026 Provision/(benefit) for
taxes on income 3,876 941 (42) - (376) 4,399 Income from continuing operations 8,779
2,346 306 - 196

11,627 Discontinued operations--net of tax 10,719 - - (10,719) - - Net income
attributable to noncontrolling interests 63 - - (38) - 25 Net income attributable to Pfizer
Inc. 19,435 2,346 306 (10,681) 196 11,602 Earnings per common share attributable to
Pfizer Inc.--diluted 2.77 0.33 0.04 (1.52) 0.03 1.65 See end of tables for notes (1)
through (6). Certain amounts may reflect rounding adjustments.
EPS amounts may not add due to rounding.

PFIZER INC. AND SUBSIDIARY COMPANIES RECONCILIATION OF GAAP REPORTED TO
NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (millions of
dollars, except per common share data) Quarter Ended September 30, 2012
Purchase Acquisition- Certain GAAP Accounting Related Discontinued Significant Non-
GAAP Reported(1) Adjustments Costs(2) Operations Items(3) Adjusted(4) Revenues \$
12,953 \$ - \$ - \$ - \$ 12,953 Cost of sales(5) 2,309 3 (75) - (24) 2,213 Selling,
informational and administrative expenses(5) 3,491 (2) (2) - (46) 3,441 Research and
development expenses(5) 1,887 1 - - (47) 1,841 Amortization of intangible assets(6)
1,211 (1,173) - - - 38 Restructuring charges and certain acquisition-related costs 312 -
(160) - (152) - Other (income)/deductions--net 937 44 - - (783) 198 Income from
continuing operations before provision for taxes on income 2,806 1,127 237 - 1,052 5,222
Provision/(benefit) for taxes on income (183) 324 43 - 1,278 1,462 Income from
continuing operations 2,989 803 194 - (226)

3,760 Discontinued operations--net of tax 225 - - (225) - - Net income attributable to
noncontrolling interests 6 - - - 6 Net income attributable to Pfizer Inc. 3,208 803 194
(225) (226) 3,754 Earnings per common share attributable to Pfizer Inc.--diluted 0.43
0.11 0.03 (0.03) (0.03) 0.50 Nine Months Ended September 30, 2012 Purchase
Acquisition- Certain GAAP Accounting Related Discontinued Significant Non-GAAP
Reported(1) Adjustments Costs(2) Operations Items(3) Adjusted(4) Revenues \$ 40,766 \$ -
\$ - \$ - \$ 40,766 Cost of sales(5) 7,068 (6) (205) - (51) 6,806 Selling, informational
and administrative expenses(5) 10,834 3 (7) - (77) 10,753 Research and development
expenses(5) 5,461 4 (5) - (386) 5,074 Amortization of intangible assets(6) 3,889 (3,726)
- - - 163 Restructuring charges and certain acquisition-related costs 1,085 - (421) - (664)
- Other (income)/deductions--net 3,264 12 - - (2,606) 670 Income from continuing
operations before provision for taxes on income 9,165 3,713 638 - 3,784 17,300

Provision/(benefit) for taxes on income 1,622 1,014 156 - 2,128 4,920 Income from continuing operations 7,543 2,699 482 - 1,656

12,380 Discontinued operations--net of tax 734 - - (734) - - Net income attributable to noncontrolling interests 22 - - - 22 Net income attributable to Pfizer Inc. 8,255 2,699 482 (734) 1,656 12,358 Earnings per common share attributable to Pfizer Inc.--diluted 1.09 0.36 0.06 (0.10) 0.22 1.64 See end of tables for notes (1) through (6). Certain amounts may reflect rounding adjustments. EPS amounts may not add due to rounding.

PFIZER INC. AND SUBSIDIARY COMPANIES NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION CERTAIN LINE ITEMS (UNAUDITED) (1) The financial statements present the three and nine months ended September 29, 2013 and September 30, 2012. Subsidiaries operating outside the United States are included for the three and nine months ended August 25, 2013 and August 26, 2012. On June 24, 2013, we completed the full disposition of our Animal Health business (Zoetis) and recognized a gain of approximately \$10.5 billion (pre-tax) related to this disposal in Discontinued operations--net of tax for the nine months ended September 29, 2013. The operating results of this business are reported as Discontinued operations--net of tax for the nine months ended September 29, 2013 and three and nine months ended September 30, 2012. On November 30, 2012, we completed the sale of our Nutrition business. The operating results of this business are reported as Discontinued operations--net of tax for the three and nine months ended September 30, 2012. (2)

Acquisition-related costs include the following: Third-Quarter Nine Months (millions of dollars)

2013

2012

2013

2012

Integration costs(a) \$ 38 \$ 79 \$ 107 \$ 279 Restructuring charges(a) 5 81 48 142 Additional depreciation--asset restructuring(b) 18 77 109 217 Total acquisition-related costs--pre-tax 61 237 264 638 Income taxes(c) (7) (43) 42 (156) Total acquisition-related costs--net of tax \$ 54 \$ 194 \$ 306 \$ 482 (a) Integration costs represent external, incremental costs directly related to integrating acquired businesses,

and primarily include expenditures for consulting and the integration of systems and processes. Restructuring charges include employee termination costs, asset impairments and other exit costs associated with business combinations. All of these costs and charges are included in Restructuring charges and certain acquisition-related costs. (b)

Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions related to acquisitions. Included in Cost of sales for the three months ended September 29, 2013. Included in Cost of sales (\$101 million) and Selling, informational and administrative expenses (\$8 million) for the nine months ended September 29, 2013. Included in Cost of sales (\$75 million) and Selling, informational and administrative expenses (\$2 million) for the three months ended September 30, 2012. Included in Cost of sales (\$205 million), Selling, informational and administrative expenses (\$7 million) and Research and development expenses (\$5 million) for the nine months ended September 30, 2012.

(c) Included in Provision/(benefit) for taxes on income. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate. The first nine months of 2013 also includes the unfavorable impact of the remeasurement of certain deferred tax liabilities resulting from plant network restructuring activities. (3)

Certain significant items include the following:

	Third-Quarter	Nine Months	(millions of dollars)
2013			
2012			
2013			
2012			

Restructuring charges(a) \$ 190 \$ 152 \$ 392 \$ 664 Implementation costs and additional depreciation--asset restructuring(b) 72 111 270 485 Patent litigation settlement (income)/expense(c) 9 - (1,342) - Other legal matters, net(d) 1 723 (99) 1,981 Gain associated with the transfer of certain product rights to an equity-method investment(e) - - (459) - Certain asset impairments and related charges(f) 440 17 929 506 Costs associated with the Zoetis IPO(g) - 32 18 93 Income associated with the transitional

manufacturing and supply agreements with Zoetis(h) (10) - (10) - Other(i) 42 17
 121 55 Total certain significant items--pre-tax 744 1,052 (180) 3,784 Income taxes(j)
 (172) (1,278) 376 (2,128) Total certain significant items--net of tax \$ 572 \$
 (226) \$ 196 \$ 1,656 (a) Primarily related to our cost-reduction and productivity
 initiatives. Included in Restructuring charges and certain acquisition-related costs. (b)
 Primarily related to our cost-reduction and productivity initiatives. Included in Cost of
 sales (\$41 million), Selling, informational and administrative expenses (\$30 million) and
 Research and development expenses (\$1 million) for the three months ended September
 29, 2013. Included in Cost of sales (\$60 million), Selling, informational and administrative
 expenses (\$106 million) and Research and development expenses (\$104 million) for the
 nine months ended September 29, 2013. Included in Cost of sales (\$18 million), Selling,
 informational and administrative expenses (\$46 million) and Research and development
 expenses (\$47 million) for the three months ended September 30, 2012. Included in Cost
 of sales (\$22 million), Selling, informational and administrative expenses (\$77 million)
 and Research and development expenses (\$386 million) for the nine months ended
 September 30, 2012. (c) Included in Other (income)/deductions--net. In the first nine
 months of 2013, reflects income from a litigation settlement with Teva Pharmaceutical
 Industries Ltd. and Sun Pharmaceutical Industries Ltd. for patent-infringement damages
 resulting from their "at-risk" launches of generic Protonix in the United States. (d)
 Included in Other (income)/deductions--net. In the first nine months of 2013, primarily
 includes an \$80 million insurance recovery related to a certain litigation matter. In the
 third quarter of 2012, primarily includes a \$491 million charge related to the resolution of
 an investigation by the U.S. Department of Justice into Wyeth's historical promotional
 practices in connection with Rapamune. In the first nine months of 2012, primarily
 includes the aforementioned \$491 million charge related to Rapamune, a \$450 million
 settlement of a lawsuit by Brigham Young University related to Celebrex, and charges for
 hormone-replacement therapy litigation. (e) Included in Other (income)/deductions--net.
 In the first nine months of 2013, represents the gain associated with the transfer of
 certain product rights to Pfizer's 49%-owned equity-method investment in China. (f)
 Primarily included in Other (income)/deductions--net. In the third quarter of 2013,
 primarily includes a loss on an option to acquire the remaining interest in a 40%-owned
 generics company in Brazil (approximately \$220 million), as well as an impairment
 charge related to an IPR&D compound. In the first nine months of 2013, also includes
 impairment charges related to developed technology (for use in the development of bone
 and cartilage) acquired in connection with our acquisition of Wyeth and two additional
 IPR&D compounds. In the first nine months of 2012, primarily includes impairment
 charges related to certain intangible asset acquired in connection with our acquisitions of
 Wyeth and King, including IPR&D intangible assets. (g) Included in Other

(income)/deductions--net. Costs incurred in connection with the initial public offering of an approximate 19.8% ownership interest in Zoetis. Includes expenditures for banking, legal, accounting and similar services. (h) Included in Revenues (\$67 million) and in Cost of sales (\$57 million) for the three and nine months ended September 29, 2013. (i) Primarily included in Other (income)/deductions--net. (j)

Included in Provision/(benefit) for taxes on income. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate. The first nine months of 2013 were unfavorably impacted by the tax liability associated with the patent litigation settlement income, by the non-deductibility of goodwill derecognized and the jurisdictional mix of the other intangible assets divested as part of the transfer of certain product rights to Pfizer's 49%-owned equity-method investment in China, as well as the non-deductibility of the loss on an option to acquire the remaining interest in a 40%-owned generics company in Brazil since we expect to retain the investment indefinitely. In the third quarter and first nine months of 2012, includes a settlement with the U.S. IRS related to audits for multiple tax years that favorably impacted GAAP Reported net income by \$1.1 billion, representing tax and interest.

(4) Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS are Non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP Adjusted income and its components and Non-GAAP Adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. (5) Exclusive of amortization of intangible assets, except as discussed in footnote (6) below. (6) Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function is included in Cost of sales, Selling, informational and administrative expenses or Research and development expenses, as appropriate. PFIZER INC. REVENUES THIRD QUARTER 2013 and 2012 (UNAUDITED)

(millions of dollars) WORLDWIDE UNITED STATES TOTAL INTERNATIONAL(a)

2013

2012 % Change 2013 2012 % Change 2013 2012 % Change

Total

Oper.

Total

Total

Oper.

TOTAL REVENUES \$ 12,643 \$ 12,953 (2 %) - \$ 5,186 \$ 5,174 - \$ 7,457 \$ 7,779 (4 %) (1 %)

REVENUES FROM

BIOPHARMACEUTICAL PRODUCTS:

\$ 11,742 \$ 12,117 (3 %) (1 %) \$ 4,747 \$ 4,769 - \$ 6,995 \$ 7,348 (5 %) (1 %) Lyrica 1,135 1,036 10 % 11 % 509 430 18 % 626 606 3 % 6 % Prevnar family 959 949 1 % 3 % 469 440 7 % 490 509 (4 %) (1 %) Enbrel (Outside the U.S. and Canada) 932 893 4 % 6 % - - - 932 893 4 % 6 % Celebrex 752 676 11 % 13 % 508 438 16 % 244 238 3 % 8 % Lipitor 533 749 (29 %) (27 %) 78 192 (59 %) 455 557 (18 %) (16 %) Viagra 460 517 (11 %) (11 %) 294 287 2 % 166 230 (28 %) (27 %) Zyvox 319 328 (3 %) (1 %) 165 158 4 % 154 170 (9 %) (6 %) Norvasc 303 319 (5 %) 2 % 11 13 (15 %) 292 306 (5 %) 3 % Sutent 278 294 (5 %) (5 %) 85 82 4 % 193 212 (9 %) (8 %) Premarin family 276 262 5 % 6 % 254 237 7 % 22 25 (12 %) 6 % BeneFIX 213 201 6 % 7 % 101 96 5 % 112 105 7 % 8 % Genotropin 183 212 (14 %) (9 %) 45 59 (24 %) 138 153 (10 %) (3 %) Vfend 193

187 3 % 5 % 18 21 (14 %) 175 166 5 % 8 % Pristiq 173 152 14 % 15 % 134 120 12 % 39
 32 22 % 25 % Chantix/Champix 154 146 5 % 9 % 82 62 32 % 72 84 (14 %) (9 %)
 Detrol/Detrol LA 131 176 (26 %) (24 %) 89 112 (21 %) 42 64 (34 %) (30 %)
 Xalatan/Xalacom 140 181 (23 %) (17 %) 8 9 (11 %) 132 172 (23 %) (17 %) ReFacto
 AF/Xyntha 148 150 (1 %) (3 %) 29 28 4 % 119 122 (2 %) (4 %) Medrol 107 113 (5 %) (4
 %) 31 24 29 % 76 89 (15 %) (13 %) Zolof 116 129 (10 %) (2 %) 14 17 (18 %) 102 112 (9
 %) 1 % Effexor 96 107 (10 %) (11 %) 36 37 (3 %) 60 70 (14 %) (15 %) Zosyn/Tazocin 104
 109 (5 %) (3 %) 47 39 21 % 57 70 (19 %) (17 %) Zithromax/Zmax 84 89 (6 %) 1 % 3 3 -
 81 86 (6 %) - Tygacil 92 82 12 % 12 % 38 37 3 % 54 45 20 % 20 % Relpax 83 92 (10 %)
 (9 %) 49 56 (13 %) 34 36 (6 %) (1 %) Fragmin 83 91 (9 %) (10 %) 2 11 (82 %) 81 80 1 %
 (1 %) Rapamune 91 92 (1 %) - 55 49 12 % 36 43 (16 %) (15 %) EpiPen 85 67 27 % 28 %
 67 52 29 % 18 15 20 % 28 % Revatio 75 135 (44 %) (44 %) 18 78 (77 %) 57 57 - 2 %
 Sulperazon 78 62 26 % 26 % - - - 78 62 26 % 26 % Cardura 70 79 (11 %) (5 %) 1 2 (50 %)
 69 77 (10 %) (5 %) Inlyta 83 29 186 % * 42 28 50 % 41 1 * * Xanax XR 69 66 5 % 5 % 13
 13 - 56 53 6 % 5 % Xalkori 73 38 92 % 92 % 35 24 46 % 38 14 171 % 164 % Toviaz 57 52
 10 % 10 % 31 29 7 % 26 23 13 % 17 % Aricept(b) 52 71 (27 %) (25 %) - - - 52 71 (27 %)
 (25 %) Caduet 52 68 (24 %) (14 %) 5 13 (62 %) 47 55 (15 %) (6 %) Inspra 53 51 4 % 5 %
 1 1 - 52 50 4 % 4 % Diflucan 59 61 (3 %) (1 %) 1 1 - 58 60 (3 %) (2 %) Somavert 56 49 14
 % 11 % 13 12 8 % 43 37 16 % 11 % Neurontin 50 52 (4 %) (2 %) 12 12 - 38 40 (5 %) (2
 %) Dalacin/Cleocin 50 74 (32 %) (30 %) 15 40 (63 %) 35 34 3 % 9 % Xeljanz 35 - * * 34 - *
 1 - * * Alliance revenues(c) 684 879 (22 %) (22 %) 605 687 (12 %) 79 192 (59 %) (57 %)
 All other biopharmaceutical products(d) 1,923 1,952 (1 %) 3 % 700 720 (3 %) 1,223
 1,232 (1 %) 7 % All other established products(d) 1,455 1,352 8 % 11 % 514
 398 29 % 941 954 (1 %) 4 % REVENUES FROM OTHER PRODUCTS: CONSUMER
 HEALTHCARE \$ 788 \$ 780 1 % 1 % \$ 396 \$ 388 2 % \$ 392 \$ 392 - - OTHER(e) \$ 113 \$
 56 * * \$ 43 \$ 17 * \$ 70 \$ 39 79 % 80 %

* Calculation not meaningful.

(a)

Total International represents Developed Europe region + Developed Rest of World region + Emerging Markets region.

Details for these regions are located on the following page.

(b)

Represents direct sales under license agreement with Eisai Co., Ltd.

(c)

Includes Enbrel (in the U.S. and Canada), Spiriva, Rebif, Aricept and Eliquis.

(d)

All other established products is a subset of All other biopharmaceutical products.

(e)

Other represents revenues generated from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization, and includes, in 2013, the revenues related to our transitional manufacturing and supply agreements with Zoetis.

Certain amounts and percentages may reflect rounding adjustments. PFIZER INC.
INTERNATIONAL REVENUES BY GEOGRAPHIC REGION THIRD QUARTER 2013 and 2012
(UNAUDITED) (millions of dollars) DEVELOPED EUROPE(a) DEVELOPED REST OF
WORLD(b) EMERGING MARKETS(c) 2013 2012 %
Change 2013 2012 % Change 2013 2012 % Change

Total

Oper.

Total

Oper.

Total

Oper.

TOTAL INTERNATIONAL REVENUES \$ 2,785 \$ 2,804 (1 %) (5 %) \$ 1,992 \$ 2,386
(17 %) (3 %) \$ 2,680 \$ 2,589 4 % 6 %

REVENUES FROM

BIOPHARMACEUTICAL PRODUCTS -

INTERNATIONAL:

\$ 2,663 \$ 2,672 - (5 %) \$ 1,901 \$ 2,287 (17 %) (3 %) \$ 2,431 \$ 2,389 2 %
5 % Lyrica 361 324 11 % 7 % 152 185 (18 %) (1 %) 113 97 16 % 18 % Plevnar
family 164 161 2 % (3 %) 116 133 (13 %) 1 % 210 215 (2 %) - Enbrel (Outside Canada)
600 555 8 % 3 % 127 148 (14 %) 2 % 205 190 8 % 15 % Celebrex 36 37 (3 %) (9 %) 115
119 (3 %) 9 % 93 82 13 % 15 % Lipitor 71 130 (45 %) (48 %) 122 207 (41 %) (32 %) 262
220 19 % 19 % Viagra 54 92 (41 %) (43 %) 36 48 (25 %) (18 %) 76 90 (16 %) (16 %)
Zyvox 81 73 11 % 6 % 35 37 (5 %) 8 % 38 60 (37 %) (29 %) Norvasc 25 27 (7 %) (15 %)
115 150 (23 %) (7 %) 152 129 18 % 17 % Sutent 96 103 (7 %) (12 %) 35 44 (20 %) (11 %)
62 65 (5 %) (1 %) Premarin family 3 2 50 % (8 %) 8 11 (27 %) (12 %) 11 12 (8 %) -
BeneFIX 67 63 6 % 3 % 33 33 - 11 % 12 9 33 % 29 % Genotropin 65 71 (8 %) (13 %) 47
56 (16 %) 5 % 26 26 - 8 % Vfend 74 68 9 % 3 % 38 42 (10 %) 9 % 63 56 13 % 13 %
Pristiq - - - 25 22 14 % 16 % 14 10 40 % 43 % Chantix/Champix 26 27 (4 %) (4 %) 35 44
(20 %) (15 %) 11 13 (15 %) 4 % Detrol/Detrol LA 11 29 (62 %) (61 %) 19 24 (21 %) (11 %)
12 11 9 % 5 % Xalatan/Xalacom 40 57 (30 %) (34 %) 56 73 (23 %) (8 %) 36 42 (14 %) (11 %)
) ReFacto AF/Xyntha 96 93 3 % (1 %) 16 18 (11 %) (3 %) 7 11 (36 %) (29 %) Medrol 22
21 5 % - 9 12 (25 %) (8 %) 45 56 (20 %) (19 %) Zolof 15 13 15 % 14 % 53 67 (21 %) (4 %)
) 34 32 6 % 6 % Effexor 22 26 (15 %) (20 %) 16 18 (11 %) (17 %) 22 26 (15 %) (7 %)
Zosyn/Tazocin 8 10 (20 %) (25 %) 4 3 33 % 6 % 45 57 (21 %) (16 %) Zithromax/Zmax 12
11 9 % 4 % 25 35 (29 %) (15 %) 44 40 10 % 14 % Tygacil 19 17 12 % 5 % 1 2 (50 %) (2 %)
) 34 26 31 % 31 % Relpax 17 17 - (3 %) 13 15 (13 %) (3 %) 4 4 - 10 % Fragmin 45 45 -
(2 %) 22 18 22 % 13 % 14 17 (18 %) (16 %) Rapamune 13 13 - (13 %) 4 5 (20 %) (8 %)
19 25 (24 %) (18 %) EpiPen - - - 18 15 20 % 28 % - - - Revatio 37 34 9 % 5 % 12 13 (8 %)
) 10 % 8 10 (20 %) (18 %) Sulperazon - - - 7 9 (22 %) (4 %) 71 53 34 % 31 % Cardura
20 22 (9 %) (10 %) 23 31 (26 %) (9 %) 26 24 8 % 4 % Inlyta 20 1 ** 19 - ** 2 - ** Xanax
XR 23 22 5 % (1 %) 9 10 (10 %) 6 % 24 21 14 % 19 % Xalkori 18 5 ** 13 8 63 % 83 % 7 1
** Toviaz 21 17 24 % 15 % 3 3 - 51 % 2 3 (33 %) 3 % Aricept(d) 9 18 (50 %) (51 %) 36 44
(18 %) (15 %) 7 9 (22 %) (23 %) Caduet 2 3 (33 %) (9 %) 35 37 (5 %) 6 % 10 15 (33 %)
(33 %) Inspra 34 31 10 % 2 % 14 15 (7 %) 11 % 4 4 - (2 %) Diflucan 13 14 (7 %) (12 %) 8

10 (20 %)	(5 %)	37	36	3 %	3 %	Somavert	35	30	17 %	10 %	4	4 -	13 %	4	3	33 %	21 %
Neurontin	11	14	(21 %)	(21 %)	9	10	(10 %)	(6 %)	18	16	13 %	16 %	Dalacin/Cleocin	8	7	14 %	4 %
5	7	(29 %)	1 %	22	20	10 %	13 %	Xeljanz	-	-	-	-	1	-	*	*	-
Alliance revenues(e)																	
26	53	(51 %)	(54 %)	44	128	(66 %)	(62 %)	9	11	(18 %)	(14 %)	All other biopharmaceutical products(f)					
343	316	9 %	2 %	364	374	(3 %)	19 %	516	542	(5 %)	(1 %)	All other established products(f)					
250	247	1 %	1 %	277	270	3 %	3 %	414	437	(5 %)	(2 %)						

REVENUES FROM OTHER PRODUCTS -

INTERNATIONAL

\$ 122	\$ 132	(8 %)	(6 %)	\$ 91	\$ 99	(8 %)	(10 %)	\$ 249	\$ 200	25 %	26 %
--------	--------	-------	-------	-------	-------	-------	--------	--------	--------	------	------

* Calculation not meaningful.

(a)

Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries.

(b)

Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.

(c)

Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe.

(d)

Represents direct sales under license agreement with Eisai Co., Ltd.

(e)

Includes Enbrel (in Canada), Spiriva, Aricept and Eliquis.

(f)

All other established products is a subset of All other biopharmaceutical products.

Certain amounts and percentages may reflect rounding adjustments. PFIZER INC.

REVENUES NINE MONTHS 2013 and 2012 (UNAUDITED) (millions of dollars)

WORLDWIDE UNITED STATES TOTAL INTERNATIONAL(a)

2013 2012 % Change 2013 2012 % Change 2013 2012 % Change

Total

Oper.

Total

Total

Oper.

TOTAL REVENUES \$ 38,026 \$ 40,766 (7 %) (5 %) \$ 15,190 \$ 16,011 (5 %) \$
22,836 \$ 24,755 (8 %) (5 %)

REVENUES FROM

BIOPHARMACEUTICAL PRODUCTS:

\$ 35,398 \$ 38,321 (8 %) (6 %) \$ 14,002 \$ 14,899 (6 %) \$ 21,396 \$ 23,422
(9 %) (5 %) Lyrica 3,335 3,026 10 % 12 % 1,438 1,229 17 % 1,897 1,797 6 % 9 %
Plevinar family 2,855 3,028 (6 %) (4 %) 1,336 1,423 (6 %) 1,519 1,605 (5 %) (3 %) Enbrel
(Outside the U.S. and Canada) 2,769 2,780 - 2 % - - 2,769 2,780 - 2 % Celebrex 2,120
1,969 8 % 9 % 1,409 1,266 11 % 711 703 1 % 6 % Lipitor 1,704 3,364 (49 %) (48 %) 335
871 (62 %) 1,369 2,493 (45 %) (43 %) Viagra 1,405 1,498 (6 %) (6 %) 819 822 - 586 676
(13 %) (12 %) Zyvox 1,007 996 1 % 3 % 511 490 4 % 496 506 (2 %) 2 % Norvasc 917
1,001 (8 %) (3 %) 31 38 (18 %) 886 963 (8 %) (2 %) Sutent 892 913 (2 %) (1 %) 261 255
2 % 631 658 (4 %) (2 %) Premarin family 793 797 (1 %) - 726 724 - 67 73 (8 %) (4 %)

BeneFIX 619 577 7 % 8 % 298 272 10 % 321 305 5 % 7 % Genotropin 570 619 (8 %) (4 %)
 145 150 (3 %) 425 469 (9 %) (4 %) Vfend 557 543 3 % 5 % 49 64 (23 %) 508 479 6 %
 9 % Pristiq 516 461 12 % 13 % 402 365 10 % 114 96 19 % 22 % Chantix/Champix 486
 496 (2 %) - 253 234 8 % 233 262 (11 %) (7 %) Detrol/Detrol LA 437 576 (24 %) (23 %)
 297 362 (18 %) 140 214 (35 %) (31 %) Xalatan/Xalacom 434 617 (30 %) (25 %) 23 30 (23 %)
 411 587 (30 %) (26 %) ReFacto AF/Xyntha 433 420 3 % 3 % 89 79 13 % 344 341 1 % -
 Medrol 343 388 (12 %) (10 %) 110 105 5 % 233 283 (18 %) (16 %) Zoloft 341 398 (14 %)
 (6 %) 30 49 (39 %) 311 349 (11 %) (2 %) Effexor 326 342 (5 %) (4 %) 128 102 25 % 198
 240 (18 %) (17 %) Zosyn/Tazocin 293 378 (22 %) (22 %) 127 175 (27 %) 166 203 (18 %)
 (17 %) Zithromax/Zmax 283 318 (11 %) (6 %) 5 9 (44 %) 278 309 (10 %) (5 %) Tygacil
 271 249 9 % 10 % 122 115 6 % 149 134 11 % 13 % Relpax 263 266 (1 %) - 161 160 1 %
 102 106 (4 %) - Fragmin 263 283 (7 %) (8 %) 21 36 (42 %) 242 247 (2 %) (3 %)
 Rapamune 261 259 1 % 2 % 152 140 9 % 109 119 (8 %) (6 %) EpiPen 230 217 6 % 7 %
 183 182 1 % 47 35 34 % 40 % Revatio 225 414 (46 %) (45 %) 52 250 (79 %) 173 164 5 %
 8 % Sulperazon 222 191 16 % 17 % - - 222 191 16 % 17 % Cardura 221 254 (13 %) (8 %)
 3 4 (25 %) 218 250 (13 %) (7 %) Inlyta 217 53 * * 112 52 115 % 105 1 * * Xanax XR
 204 203 - 2 % 36 38 (5 %) 168 165 2 % 3 % Xalkori 193 78 147 % 151 % 98 56 75 % 95
 22 * * Toviaz 174 150 16 % 16 % 89 82 9 % 85 68 25 % 26 % Aricept(b) 173 249 (31 %)
 (30 %) - - 173 249 (31 %) (30 %) Caduet 164 191 (14 %) (9 %) 16 26 (38 %) 148 165
 (10 %) (4 %) Inspra 164 156 5 % 9 % 4 4 - 160 152 5 % 9 % Diflucan 164 185 (11 %) (9 %)
 2 4 (50 %) 162 181 (10 %) (8 %) Somavert 159 143 11 % 11 % 38 33 15 % 121 110
 10 % 10 % Neurontin 158 172 (8 %) (6 %) 33 37 (11 %) 125 135 (7 %) (5 %)
 Dalacin/Cleocin 149 176 (15 %) (13 %) 45 72 (38 %) 104 104 - 4 % Xeljanz 68 - * * 67 - *
 1 - * * Alliance revenues(c) 2,187 2,577 (15 %) (15 %) 1,901 1,908 - 286 669 (57 %) (56 %)
 All other biopharmaceutical products(d) 5,833 6,350 (8 %) (5 %) 2,045 2,586 (21 %)
 3,788 3,764 1 % 6 % All other established products(d) 4,278 4,360 (2 %) 1 %
 1,378 1,484 (7 %) 2,900 2,876 1 % 5 % REVENUES FROM OTHER PRODUCTS:
 CONSUMER HEALTHCARE \$ 2,399 \$ 2,276 5 % 5 % \$ 1,111 \$ 1,054 5 % \$ 1,288 \$ 1,222 5
 % 5 % OTHER(e) \$ 229 \$ 169 36 % 36 % \$ 77 \$ 58 33 % \$ 152 \$ 111 37 %
 39 % * Calculation not meaningful.

(a)

Total International represents Developed Europe + Developed Rest of World + Emerging Markets.

Details for these regions are located on the following page.

(b)

Represents direct sales under license agreement with Eisai Co., Ltd.

(c)

Includes Enbrel (in the U.S. and Canada), Spiriva, Rebif, Aricept and Eliquis.

(d)

All other established products is a subset of All other biopharmaceutical products.

(e)

Other represents revenues generated from Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales organization, and includes, in 2013, the revenues related to our transitional manufacturing and supply agreements with Zoetis.

Certain amounts and percentages may reflect rounding adjustments. PFIZER INC.
INTERNATIONAL REVENUES BY GEOGRAPHIC REGION NINE MONTHS 2013 and 2012
(UNAUDITED) (millions of dollars) DEVELOPED EUROPE(a) DEVELOPED REST OF
WORLD(b) EMERGING MARKETS(c) 2013 2012 %
Change 2013 2012 % Change 2013 2012 % Change
Total

Oper.

Total

Oper.

Total

Oper.

TOTAL INTERNATIONAL REVENUES	\$ 8,502	\$ 9,433	(10 %)	(11 %)	\$ 6,139	\$ 7,383
	(17 %)	(7 %)	\$ 8,195	\$ 7,939	3 %	6 %

REVENUES FROM

BIOPHARMACEUTICAL PRODUCTS -

INTERNATIONAL:

\$ 8,083 \$ 9,026 (10 %) (12 %) \$ 5,847 \$ 7,088 (18 %) 7 % \$ 7,466 \$ 7,308
2 % 5 % Lyrica 1,045 955 9 % 8 % 497 526 (6 %) 8 % 355 316 12 % 15 % Plevnar
family 507 496 2 % - 385 459 (16 %) (7 %) 627 650 (4 %) (2 %) Enbrel (Outside Canada)
1,754 1,691 4 % 2 % 379 451 (16 %) (4 %) 636 638 - 7 % Celebrex 110 121 (9 %) (11 %)
334 341 (2 %) 8 % 267 241 11 % 11 % Lipitor 227 1,042 (78 %) (79 %) 381 777 (51 %)
(46 %) 761 674 13 % 14 % Viagra 228 267 (15 %) (15 %) 113 152 (26 %) (21 %) 245 257
(5 %) (4 %) Zyvox 238 224 6 % 4 % 101 115 (12 %) 1 % 157 167 (6 %) - Norvasc 80 91
(12 %) (14 %) 364 488 (25 %) (13 %) 442 384 15 % 14 % Sutent 293 325 (10 %) (11 %)
103 128 (20 %) (11 %) 235 205 15 % 18 % Premarin family 7 7 - (6 %) 26 27 (4 %) 1 %
34 39 (13 %) (8 %) BeneFIX 186 182 2 % 1 % 101 98 3 % 11 % 34 25 36 % 36 %
Genotropin 197 224 (12 %) (14 %) 147 166 (11 %) 3 % 81 79 3 % 9 % Vfend 222 203 9 %
8 % 110 118 (7 %) 7 % 176 158 11 % 13 % Pristiq - - - 74 62 19 % 21 % 40 34 18 % 24
% Chantix/Champix 88 94 (6 %) (6 %) 109 132 (17 %) (12 %) 36 36 - 4 % Detrol/Detrol LA
41 97 (58 %) (58 %) 63 74 (15 %) (7 %) 36 43 (16 %) (15 %) Xalatan/Xalacom 117 220
(47 %) (48 %) 172 232 (26 %) (15 %) 122 135 (10 %) (7 %) ReFacto AF/Xyntha 278 274 1
% - 52 44 18 % 22 % 14 23 (39 %) (36 %) Medrol 67 70 (4 %) (6 %) 29 36 (19 %) (8 %)
137 177 (23 %) (21 %) Zoloft 47 44 7 % 5 % 163 207 (21 %) (7 %) 101 98 3 % 6 %
Effexor 70 84 (17 %) (18 %) 51 80 (36 %) (36 %) 77 76 1 % 5 % Zosyn/Tazocin 30 37 (19
%) (21 %) 10 11 (9 %) (16 %) 126 155 (19 %) (17 %) Zithromax/Zmax 44 45 (2 %) (5 %)
95 134 (29 %) (17 %) 139 130 7 % 8 % Tygacil 53 50 6 % 4 % 5 5 - 15 % 91 79 15 % 19
% Relpax 50 50 - (2 %) 38 43 (12 %) (2 %) 14 13 8 % 10 % Fragmin 130 135 (4 %) (5 %)
65 58 12 % 11 % 47 54 (13 %) (13 %) Rapamune 38 39 (3 %) (5 %) 13 13 - 2 % 58 67 (13
%) (8 %) EpiPen - - - 47 35 34 % 40 % - - - Revatio 112 100 12 % 10 % 37 40 (8 %) 8 %
24 24 - 1 % Sulperazon - - - 20 27 (26 %) (9 %) 202 164 23 % 21 % Cardura 64 72 (11
%) (12 %) 76 102 (25 %) (12 %) 78 76 3 % 3 % Inlyta 46 1 ** 56 - ** 3 - ** Xanax XR 73
65 12 % 10 % 26 33 (21 %) (9 %) 69 67 3 % 3 % Xalkori 41 11 ** 33 9 ** 21 2 ** Toviaz
61 54 13 % 11 % 15 7 114 % 146 % 9 7 29 % 35 % Aricept(d) 34 93 (63 %) (64 %) 116
126 (8 %) (7 %) 23 30 (23 %) (21 %) Caduet 9 10 (10 %) (10 %) 106 108 (2 %) 7 % 33 47
(30 %) (28 %) Inspra 104 96 8 % 6 % 42 44 (5 %) 12 % 14 12 17 % 24 % Diflucan 37 47
(21 %) (22 %) 24 30 (20 %) (9 %) 101 104 (3 %) (2 %) Somavert 98 90 9 % 7 % 12 12 -
13 % 11 8 38 % 33 % Neurontin 37 45 (18 %) (18 %) 28 31 (10 %) (6 %) 60 59 2 % 6 %
Dalacin/Cleocin 23 23 - (2 %) 16 21 (24 %) (11 %) 65 60 8 % 11 % Xeljanz - - - 1 - * * - - -
- Alliance revenues(e) 89 204 (56 %) (57 %) 164 414 (60 %) (57 %) 33 51 (35 %) (34 %)

All other biopharmaceutical products(f)	1,108	1,048	6 %	4 %	1,048	1,072	(2 %)	12 %
1,632	1,644	(1 %)	4 %	All other established products(f)	795	769	3 %	2 %
786	(1 %)	11 %	1,326	1,321	-	3 %		

REVENUES FROM OTHER PRODUCTS -

INTERNATIONAL

\$ 419	\$ 407	3 %	2 %	\$ 292	\$ 295	(1 %)	-	\$ 729	\$ 631	16 %	17 % *
--------	--------	-----	-----	--------	--------	-------	---	--------	--------	------	--------

Calculation not meaningful.

(a)

Developed Europe region includes the following markets: Western Europe, Finland and the Scandinavian countries.

(b)

Developed Rest of World region includes the following markets: Australia, Canada, Japan, New Zealand and South Korea.

(c)

Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe.

(d)

Represents direct sales under license agreement with Eisai Co., Ltd.

(e)

Includes Enbrel (in Canada), Spiriva, Aricept and Eliquis.

(f)

All other established products is a subset of All other biopharmaceutical products.

Certain amounts and percentages may reflect rounding adjustments.

DISCLOSURE NOTICE: The information contained in this earnings release and the attachments is as of October 29, 2013. We assume no obligation to update forward-looking statements contained in this earnings release and the attachments as a result of new information or future events or developments.

This earnings release and the attachments contain forward-looking statements about our future operating and financial performance, business plans and prospects, in-line products and product candidates, strategic reviews, capital allocation, business-development plans, and plans relating to share repurchases and dividends, among other things, that involve substantial risks and uncertainties. You can identify these statements by the fact that they use future dates or use words such as “will,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “forecast,” “goal,” “objective,” “aim” and other words and terms of similar meaning. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:

the outcome of research and development activities, including, without limitation, the ability to meet anticipated clinical trial commencement and completion dates, regulatory submission and approval dates, and launch dates for product candidates, as well as the possibility of unfavorable clinical trial results, including unfavorable new clinical data and additional analyses of existing clinical data; decisions by regulatory authorities regarding whether and when to approve our drug applications, as well as their decisions regarding labeling, ingredients and other matters that could affect the availability or commercial potential of our products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the outcome of post-approval clinical trials, which could result in the loss of marketing approval for a product or changes in the labeling for, and/or increased or new concerns about the safety or efficacy of, a product that could affect its availability or commercial potential; the success of external business-development activities; competitive developments, including the impact on our competitive position of new product entrants, in-line branded products, generic products, private label products and product candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates; the implementation by the FDA of an abbreviated legal pathway to approve biosimilar products, which could subject our biologic products to competition from biosimilar products in the U.S., with attendant competitive pressures, after the expiration of any applicable exclusivity period and patent rights; the ability to meet generic and branded competition after the loss of patent protection for our products or competitor products; the ability to successfully market both new and existing products domestically and internationally; difficulties or delays in manufacturing; trade buying patterns; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; the impact of the U.S. Budget Control Act of 2011 (the Budget Control Act) and the deficit-reduction actions to be taken pursuant to the Budget Control Act in order to achieve the deficit-reduction targets provided for therein, and the impact of any

broader deficit-reduction efforts; the inability of the U.S. federal government to conduct drug review and approval activities or to satisfy its financial obligations, including under Medicare, Medicaid and other publicly funded or subsidized health programs, that may result from the possible failure of the U.S. federal government in early 2014 to provide funding to avoid a partial or total shutdown of its operations and/or to suspend enforcement of or to increase the federal debt ceiling; the impact of U.S. healthcare legislation enacted in 2010 – the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act – and of any modification or repeal of any of the provisions thereof; U.S. federal or state legislation or regulatory action affecting, among other things: pharmaceutical product pricing, reimbursement or access, including under Medicaid, Medicare and other publicly funded or subsidized health programs; the importation of prescription drugs from outside the U.S. at prices that are regulated by governments of various foreign countries; direct-to-consumer advertising and interactions with healthcare professionals; and the use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on the cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to innovative medicines; legislation or regulatory action in markets outside the U.S. affecting pharmaceutical product pricing, reimbursement or access, including, in particular, continued government-mandated price reductions for certain biopharmaceutical products in certain European and emerging market countries; the exposure of our operations outside the U.S. to possible capital and exchange controls, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, as well as political unrest and unstable governments and legal systems; contingencies related to actual or alleged environmental contamination; claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates; any significant breakdown, infiltration, or interruption of our information technology systems and infrastructure; legal defense costs, insurance expenses, settlement costs, the risk of an adverse decision or settlement and the adequacy of reserves related to product liability, patent protection, government investigations, consumer, commercial, securities, antitrust, environmental and tax issues, ongoing efforts to explore various means for resolving asbestos litigation, and other legal proceedings; our ability to protect our patents and other intellectual property, both domestically and internationally; interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates; governmental laws and regulations affecting domestic and foreign operations, including, without limitation, tax obligations and changes affecting the tax treatment by the U.S. of income earned outside of the U.S. that may result from pending and possible future proposals; any significant issues involving our

largest wholesaler customers, which account for a substantial portion of our revenues; the possible impact of the increased presence of counterfeit medicines in the pharmaceutical supply chain on our revenues and on patient confidence in the integrity of our medicines; any significant issues that may arise related to the outsourcing of certain operational and staff functions to third parties, including with regard to quality, timeliness and compliance with applicable legal requirements and industry standards; changes in U.S. generally accepted accounting principles; uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions and recent and possible future changes in global financial markets; and the related risk that our allowance for doubtful accounts may not be adequate; any changes in business, political and economic conditions due to actual or threatened terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas; growth in costs and expenses; changes in our product, segment and geographic mix; and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product recalls and withdrawals and other unusual items, including our ability to realize the projected benefits of our cost-reduction and productivity initiatives, including those related to our research and development organization, and of our plan to internally separate our commercial operations into three, new, global businesses effective January 1, 2014.

A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2012 and in our reports on Form 10-Q, in each case including in the sections thereof captioned "Forward-Looking Information and Factors That May Affect Future Results" and "Item 1A. Risk Factors", and in our reports on Form 8-K.

This earnings release may include discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data.

Contacts: Media Joan Campion 212.733.2798 Investors Chuck Triano 212.733.3901
Suzanne Harnett 212.733.8009